Ms. Maryam Marissen reports

PANGENOMIC HEALTH SUBSIDIARY ANNOUNCES FIRST SALE OF BDNF BIOMARKER TESTS

Pangenomic Health Inc.'s subsidiary, MUJN Diagnostics Inc., has launched its BDNF (brain-derived neurotrophic factor) mental health biomarker health assessment service and completed its first sale of the point-of-care test marketed to health clinics in Canada.

"Our strategy is to continue to expand MUJN Diagnostic's health services beyond our initial vitamin D assessments to include rapid in-clinic access to a panel of mental health patient point-of-care biomarker assessments," said Vincent Lum, chief executive officer of MUJN Diagnostics and co-founder of Pangenomic Health. "Our newest product is the MUJN BDNF biomarker assessment for mental health and wellness. Changes in BDNF levels provide important information for health practitioners when considering treatment options for patients with brain health concerns such as major depressive disorder."

Current clinical research on BDNF has found that:

• BDNF plays a significant role in the survival and development, as well as creation, of new neurons. BDNF has been shown to be a critical regulator of neurocognitive functions and impairment of BDNF levels have been connected to a variety of mental health diseases.
• Decrease in the expression of BDNF is seen in many neurological problems such as depression, Alzheimer's, Parkinson's, Huntington's and bipolar disease.
• BDNF serum levels are lower in patients with major depressive disorder compared with those in healthy controls. Pharmacological treatments often lead to an increase in BDNF levels, which correlates with an improvement in a patient's mental health condition.

About MUJN Diagnostics Inc.

MUJN Diagnostics is a wholly owned subsidiary of Pangenomic Health and is focused on developing a decision support system for alternative health care providers. MUJN's decision support system will include biomarker diagnostics, symptom and treatment tracking, and personalized health analytics, with the goal of empowering health care providers and their patients toward better outcomes.

About Pangenomic Health Inc.

Pangenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The company's initial focus is to support mental health. Registered as a British Columbia benefit company, Pangenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

We seek Safe Harbor.